Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
1 to 13 of 13  Show

Literature citations Results

Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.

Ostrow S.L., Simon E., Prinz E., Bick T., Shentzer T., Nagawkar S.S., Sabo E., Ben-Izhak O., Hershberg R., Hershkovitz D.

Sci Rep 6:21927-21927(2016) · Mapped (18)

Toll-like Receptor 4 Ligands Down-regulate Fcgamma Receptor IIb (FcgammaRIIb) via MARCH3 Protein-mediated Ubiquitination.

Fatehchand K., Ren L., Elavazhagan S., Fang H., Mo X., Vasilakos J.P., Dietsch G.N., Hershberg R.M., Tridandapani S., Butchar J.P.

J. Biol. Chem. 291:3895-3904(2016) · Mapped (8)

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.

Stephenson R.M., Lim C.M., Matthews M., Dietsch G., Hershberg R., Ferris R.L.

Cancer Immunol. Immunother. 62:1347-1357(2013) · Mapped (46)

Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Stover A.G., Da Silva Correia J., Evans J.T., Cluff C.W., Elliott M.W., Jeffery E.W., Johnson D.A., Lacy M.J., Baldridge J.R., Probst P. et al.

J. Biol. Chem. 279:4440-4449(2004) · Mapped (2)

Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.

Swisher E.M., Harrell M.I., Norquist B.M., Walsh T., Brady M., Lee M., Hershberg R., Kalli K.R., Lankes H., Konnick E.Q. et al.

JAMA Oncol 2:370-372(2016) · Mapped (190)

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow L.Q.M., Morishima C., Eaton K.D., Baik C.S., Goulart B.H., Anderson L.N., Manjarrez K.L., Dietsch G.N., Bryan J.K., Hershberg R.M. et al.

Clin. Cancer Res. 23:2442-2450(2017) · Mapped (5)

Intestinal epithelial cells secrete exosome-like vesicles.

van Niel G., Raposo G., Candalh C., Boussac M., Hershberg R., Cerf-Bensussan N., Heyman M.

Gastroenterology 121:337-349(2001)

Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice.

Burich A., Hershberg R., Waggie K., Zeng W., Brabb T., Westrich G., Viney J.L., Maggio-Price L.

Am. J. Physiol. Gastrointest. Liver Physiol. 281:G764-78(2001) · Mapped (6)

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S., Fatehchand K., Santhanam V., Fang H., Ren L., Gautam S., Reader B., Mo X., Cheney C., Briercheck E. et al.

J. Immunol. 194:2786-2795(2015) · Mapped (11)

Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells.

van de Wal Y., Corazza N., Allez M., Mayer L.F., Iijima H., Ryan M., Cornwall S., Kaiserlian D., Hershberg R., Koezuka Y. et al.

Gastroenterology 124:1420-1431(2003) · Mapped (7)

Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway.

Dickinson B.L., Claypool S.M., D'Angelo J.A., Aiken M.L., Venu N., Yen E.H., Wagner J.S., Borawski J.A., Pierce A.T., Hershberg R. et al.

Mol. Biol. Cell 19:414-423(2008) · Mapped (5)

Bacterial flagellin is a dominant antigen in Crohn disease.

Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., Fort M., Hershberg R.M.

J. Clin. Invest. 113:1296-1306(2004) · UniProtKB (2)

Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.

van Haren S.D., Dowling D.J., Foppen W., Christensen D., Andersen P., Reed S.G., Hershberg R.M., Baden L.R., Levy O.

J. Immunol. 197:4413-4424(2016) · Mapped (7)

1 to 13 of 13  Show
UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again